Formation Bio Raises $372 million Series D
Formation Bio raised $372M in Series D financing led by a16z, with participation from Sanofi and other investors. Formation Bio secured $372 million in Series D funding to expand its drug pipeline and AI-driven drug development platform. The funding round was led by a16z, with participation from Sanofi and other.
What it does
Formation Bio secured $372 million in Series D funding to expand its drug pipeline and AI-driven drug development platform. The funding round was led by a16z, with participation from Sanofi and other. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
The funding round is the clearest current traction signal available for Formation Bio in the source bundle. Additional customer, revenue, and growth metrics can be layered in as source coverage expands.
Trend impact
Formation Bio's round adds a current private-market signal to Healthcare & Life Sciences. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- Recent · Series D · $372 million · a16z, with participation from Sanofi and other investors
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round